Laconi Ezio, Laconi Sergio
Dipartimento di Scienze Biomediche e Biotecnologie, Università di Cagliari, c/o Oncology Hospital "A. Businco", Via Jenner, 09125, Cagliari, Italy.
Semin Cell Dev Biol. 2002 Dec;13(6):433-8. doi: 10.1016/s1084952102001313.
Hepatocyte transplantation (HTx) is technically feasible and can be clinically beneficial. Current research focuses on optimizing parameters which relate to the outcome of HTx, including site of transplantation, cell number and, most notably, the preferred cell type to be transplanted (differentiated adult vs. fetal hepatocytes vs. putative progenitor or precursor cells). However, the single major impediment towards the clinical effectiveness of HTx is the limited expansion of donor cells in the recipient liver. To this end, a relative growth advantage must be present or is to be imposed on transplanted hepatocytes versus resident cells. Possible strategies are presented and discussed.
肝细胞移植(HTx)在技术上是可行的,并且可能具有临床益处。当前的研究集中于优化与肝细胞移植结果相关的参数,包括移植部位、细胞数量,最显著的是,移植的首选细胞类型(分化的成体肝细胞与胎儿肝细胞与假定的祖细胞或前体细胞)。然而,肝细胞移植临床有效性的单一主要障碍是供体细胞在受体肝脏中的有限扩增。为此,与驻留细胞相比,移植的肝细胞必须具有相对生长优势或施加这种优势。文中提出并讨论了可能的策略。